Skip to content

The implementation of microarrays in cancer diagnosis (microarray prognostics in breast cancer)

The implementation of microarrays in cancer diagnosis (microarray prognostics in breast cancer)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71917916
Enrollment
750
Registered
2007-02-27
Start date
2004-01-22
Completion date
Unknown
Last updated
2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

Sponsors

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI AVL) (The Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Female patients 2. With primary operable unifocal breast cancer 3. Without clinical signs of lymph node involvement or distant metastasis 4. Younger than 55 years of age

Exclusion criteria

Exclusion criteria: A prior history of any malignancy with the exception of cervical dysplasia and basal cell carcinoma.

Design outcomes

Primary

MeasureTime frame
The amount of successfully performed diagnostic microarray tests as a proportion of the total number of accrued patients.

Secondary

MeasureTime frame
1. To assess the proportion of a 'high' versus a 'low' risk profile in lymph node negative breast cancer patients 2. To assess the concordance between the 70-gene microarray risk profile and the metastasis risk as assessed with current Dutch guidelines based on clinicopathological factors (such as age, pT, tumor grade, hormonal receptor-status)

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 13, 2026